Rockville, MD (May 2, 2022) - Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today that Anya Derbij, MD has joined the company as Vice President of Clinical Operations.
“We’re very pleased to have Anya join the Cellphire team,” said Allan Alexander, MD, Chief Medical Officer. “She brings a wealth of experience, technical knowledge, and team-building skills to Cellphire continuing the maturation of our Clinical Development Department. With the strong technologies we have in development, our ability to collect well-controlled, objective clinical trial data will continue to move towards industry-leading excellence under Anya’s guidance.”
Dr. Derbij has worked for over 20 years in industry and joins the team as Vice President of Clinical Operations after successfully managing a pivotal trial in ophthalmic gene therapy during the worst of the COVID-19pandemic. Dr. Derbij has extensive experience working in start-up companies. Her areas of therapeutic experience include clinical trials in Oncology, Immunology, and Virology. Anya brings a wealth of trial conduct and process expertise. As a member of the Thrombosomes Core Team she will provide key leadership as we seek to broaden and accelerate the clinical development of Thrombosomes and Cryopreserved Platelets.
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications from stopping bleeding, healing wounds, and imaging to targeted drug delivery and regenerative medicine. For more information, visit www.cellphire.com.
The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021.
This(CPP) work is supported by the U.S. Army Medical Research and Development Command under Contract No. W81XWH20C0030.
Media and Investor Relations
Director, Business Operations